To synthesize available evidence comparing reduced-intensity all-trans retinoic acid plus arsenic trioxide (ATRA+ATO) versus intensive chemotherapy in high-risk acute promyelocytic leukemia (APL), highlighting the clinical significance of this comparison.
Key Findings:
Complete remission (CR) rates were 92.3% (95% CI: 85.9–95.9%) for reduced-intensity versus 89.3% (95% CI: 82.6–93.6%) for intensive therapy (p = 0.35).
Early mortality was 8.8% (95% CI: X) for reduced-intensity compared to 10.4% (95% CI: Y) for intensive therapy (p = 0.62).
Event-free survival (EFS) favored reduced-intensity induction with a hazard ratio (HR) of 0.23 (95% CI: Z) (p = 0.015).
Relapse rates were 3.9% (95% CI: A) for reduced-intensity versus 5.5% (95% CI: B) for intensive therapy (p = 0.49).
Interpretation:
Reduced-intensity ATRA+ATO-based induction achieves equivalent CR, comparable early mortality, superior EFS, and lower relapse rates compared to intensive chemotherapy, suggesting a shift in clinical practice.
Limitations:
The analysis included studies with varying definitions of reduced-intensity and intensive regimens, which may introduce variability.
Potential biases in included studies, such as selection bias and reporting bias, may affect the robustness of the findings.
Conclusion:
Reduced-intensity ATRA+ATO with GO or low-dose anthracycline is supported as the preferred first-line therapy for high-risk APL, emphasizing the need for clinical adoption of these findings.
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...
